Dapagliflozin Patient Satisfaction Survey
Direct to Patient Survey to Examine Treatment Satisfaction and Experience With Dapagliflozin Compared to Sulfonylureas
1 other identifier
observational
653
1 country
1
Brief Summary
The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2016
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 2, 2016
CompletedFirst Posted
Study publicly available on registry
June 20, 2016
CompletedStudy Start
First participant enrolled
June 22, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 29, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
October 29, 2018
CompletedOctober 30, 2019
October 1, 2019
2.4 years
June 2, 2016
October 28, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Condition-specific treatment satisfaction
Condition-specific treatment satisfaction as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
2 weeks
Secondary Outcomes (4)
Medical Outcomes Study (MOS) Short Form Health Survey SF-12 or SF-36
4 weeks
Morisky Medication Adherence Scale
1 month
Hypoglycemia Fear Survey
4 weeks
Self-reported body weight
1 month
Study Arms (2)
Dapagliflozin, dapagliflozin/met ER
Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
Sulfonylurea
Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
Eligibility Criteria
Type 2 Diabetes patients with administrative claims data from Optum Research Database (US Commercial Claims Data)
You may qualify if:
- At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication during the 6 months prior to sample identification.
- Evidence of T2D diagnosis.
- Age ≥18 as of the drug index date.
- months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date.
- Self-reported T2D diagnosis during the patient interview.
You may not qualify if:
- Patients with evidence of type 1 diabetes mellitus and unknown type
- Patients who are pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
- Optum, Inc.collaborator
Study Sites (1)
Reasearch Site
Eden Prairie, Minnesota, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Kelly Bell, PharmD, MSPhr
AstraZeneca
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 2, 2016
First Posted
June 20, 2016
Study Start
June 22, 2016
Primary Completion
October 29, 2018
Study Completion
October 29, 2018
Last Updated
October 30, 2019
Record last verified: 2019-10